size : | Price | Quantity | |
---|---|---|---|
5 mg | $60.00 | ||
25 mg | $240.00 |
Indirubin-3′-monoxime (160807-49-8) is a potent GSK-3β inhibitor (IC50=22 nM).1 Also inhibits CDK1 (IC50=180 nM) and CDK5 (IC50=100 nM).1 Displays antimitotic properties and induces endoreplication following prophase arrest in HBL-100 cells.2 Possesses antiangiogenic activity.3 Indirubin-3′-monoxime attenuates β-amyloid-associated neuropathology in a mouse model of Alzheimer’s disease.4 Cell permeable.
References/Citations:
1) Leclerc et al. (2001), Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer’s disease. A property common to most cyclin-dependent kinase inhibitors?; J. Biol. Chem., 276 251
2) Damiens et al. (2001), Anti-mitotic properties of indirubin-3′-monoximine, a CDK/GSK-3 inhibitor: induction of endoreplication following prophase arrest; Oncogene, 20 3786
3) Kim et al. (2011), Indirubin-3′-monoxime, a derivative of a chinese antileukemia medicine, inhibits angiogenesis; J. Cell. Biochem., 112 1384
4) Ding et al. (2010), Indirubin-3′-monoxime rescues spatial memory deficits and attenuates beta-amyloid-associated neuropathology in a mouse model of Alzheimer’s disease; Neurobiol. Dis., 39 156
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
Indirubin-3′-monoxime (160807-49-8) is a potent GSK-3β inhibitor (IC50=22 nM).1 Also inhibits CDK1 (IC50=180 nM) and CDK5 (IC50=100 nM).1 Displays antimitotic properties and induces endoreplication following prophase arrest in HBL-100 cells.2 Possesses antiangiogenic activity.3 Indirubin-3′-monoxime attenuates β-amyloid-associated neuropathology in a mouse model of Alzheimer’s disease.4 Cell permeable.
References/Citations:
1) Leclerc et al. (2001), Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer’s disease. A property common to most cyclin-dependent kinase inhibitors?; J. Biol. Chem., 276 251
2) Damiens et al. (2001), Anti-mitotic properties of indirubin-3′-monoximine, a CDK/GSK-3 inhibitor: induction of endoreplication following prophase arrest; Oncogene, 20 3786
3) Kim et al. (2011), Indirubin-3′-monoxime, a derivative of a chinese antileukemia medicine, inhibits angiogenesis; J. Cell. Biochem., 112 1384
4) Ding et al. (2010), Indirubin-3′-monoxime rescues spatial memory deficits and attenuates beta-amyloid-associated neuropathology in a mouse model of Alzheimer’s disease; Neurobiol. Dis., 39 156
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass
For Postdoc
Customers!
Website Created by Advanta Advertising LLC.